|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
InKine Pharmaceutical Company, Inc. (INKP) CEO To Open Nasdaq Stock Market In Honor Of Colorectal Cancer Awareness Month
10/19/2005 5:13:04 PM
BLUE BELL, Pa.--(BUSINESS WIRE)--March 18, 2005--InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that Leonard S. Jacob, M.D., Ph.D., Chairman and Chief Executive Officer of InKine will open the Nasdaq stock market in New York on March 22, 2005 in honor of Colorectal Cancer Awareness Month. Dr. Jacob will be joined by members of InKine's senior management team and senior representatives from the Colon Cancer Alliance (CCA) and the Crohn's and Colitis Foundation of America (CCFA).
The American Cancer Society estimates that 145,290 cases of colorectal cancer will be diagnosed in 2005 and 56,290 deaths will occur. Colorectal cancer is the second leading cause of cancer death in the United States, yet it is highly preventable and treatable with simple screening exams such as colonoscopy. A recent published study cited that liquid bowel preparations are the most common deterrent to patients undergoing colonoscopy screening. InKine is the manufacturer of Visicol(R) tablets, the first and only FDA approved, patient preferred, tablet purgative indicated for bowel cleansing prior to colonoscopy.
|
|
|
|
|
|
|
|
|
|
|